Early combination therapy with bromocriptine and levodopa in parkinson's disease
Identifieur interne : 005D99 ( Main/Exploration ); précédent : 005D98; suivant : 005E00Early combination therapy with bromocriptine and levodopa in parkinson's disease
Auteurs : Factor [États-Unis] ; William J. Weiner [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 1993.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Bromocriptine, Levodopa.
- chemical , therapeutic use : Bromocriptine, Levodopa.
- drug therapy : Parkinson Disease.
- Drug Therapy, Combination, Female, Humans, Male, Treatment Outcome.
Abstract
The use of early combination therapy with bromocriptine (Br) and levodopa (LD) in Parkinson's disease is controversial. It has been suggested that treatment with this regimen would prevent or delay the onset of motor fluctuations and dyskinesia. Thus, some have recommended it as a standard of care. This recommendation is based on the theory that LD may accelerate the progression of PD and clinical experience using Br monotherapy in early Parkinson's disease, which suggested that Br causes fewer late complications. This article reviews these arguments and shows that the theories are uproven. A single, uncontrolled trial is often referred to as evidence for efficacy of early combination therapy. We critically review this and five other studies which have evaluated the treatment strategy. We show that the literature is often misleading and that these trials do not support the efficacy of early combination therapy. We conclude that there is no justifiable reason to use a combination of Br and LD in early parkinsonian patients.
Url:
DOI: 10.1002/mds.870080302
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001C78
- to stream Istex, to step Curation: 001C78
- to stream Istex, to step Checkpoint: 004066
- to stream PubMed, to step Corpus: 004C21
- to stream PubMed, to step Curation: 004C21
- to stream PubMed, to step Checkpoint: 004C63
- to stream Ncbi, to step Merge: 004953
- to stream Ncbi, to step Curation: 004953
- to stream Ncbi, to step Checkpoint: 004953
- to stream Main, to step Merge: 009038
- to stream Main, to step Curation: 005D99
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Early combination therapy with bromocriptine and levodopa in parkinson's disease</title>
<author><name sortKey="Factor" sort="Factor" uniqKey="Factor" last="Factor">Factor</name>
</author>
<author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J." last="Weiner">William J. Weiner</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:3E9EB45C888D40961318899650513719A0D92969</idno>
<date when="1993" year="1993">1993</date>
<idno type="doi">10.1002/mds.870080302</idno>
<idno type="url">https://api.istex.fr/document/3E9EB45C888D40961318899650513719A0D92969/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001C78</idno>
<idno type="wicri:Area/Istex/Curation">001C78</idno>
<idno type="wicri:Area/Istex/Checkpoint">004066</idno>
<idno type="wicri:doubleKey">0885-3185:1993:Factor:early:combination:therapy</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:8341289</idno>
<idno type="wicri:Area/PubMed/Corpus">004C21</idno>
<idno type="wicri:Area/PubMed/Curation">004C21</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004C63</idno>
<idno type="wicri:Area/Ncbi/Merge">004953</idno>
<idno type="wicri:Area/Ncbi/Curation">004953</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004953</idno>
<idno type="wicri:doubleKey">0885-3185:1993:Factor S:early:combination:therapy</idno>
<idno type="wicri:Area/Main/Merge">009038</idno>
<idno type="wicri:Area/Main/Curation">005D99</idno>
<idno type="wicri:Area/Main/Exploration">005D99</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Early combination therapy with bromocriptine and levodopa in parkinson's disease</title>
<author><name sortKey="Factor" sort="Factor" uniqKey="Factor" last="Factor">Factor</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Albany Medical College, Albany, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J." last="Weiner">William J. Weiner</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Miami School of Medicine, Miami, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1993">1993</date>
<biblScope unit="vol">8</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="257">257</biblScope>
<biblScope unit="page" to="262">262</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">3E9EB45C888D40961318899650513719A0D92969</idno>
<idno type="DOI">10.1002/mds.870080302</idno>
<idno type="ArticleID">MDS870080302</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bromocriptine</term>
<term>Bromocriptine (adverse effects)</term>
<term>Bromocriptine (therapeutic use)</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson's disease</term>
<term>Therapy</term>
<term>Treatment Outcome</term>
<term>early combination</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Bromocriptine</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bromocriptine</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The use of early combination therapy with bromocriptine (Br) and levodopa (LD) in Parkinson's disease is controversial. It has been suggested that treatment with this regimen would prevent or delay the onset of motor fluctuations and dyskinesia. Thus, some have recommended it as a standard of care. This recommendation is based on the theory that LD may accelerate the progression of PD and clinical experience using Br monotherapy in early Parkinson's disease, which suggested that Br causes fewer late complications. This article reviews these arguments and shows that the theories are uproven. A single, uncontrolled trial is often referred to as evidence for efficacy of early combination therapy. We critically review this and five other studies which have evaluated the treatment strategy. We show that the literature is often misleading and that these trials do not support the efficacy of early combination therapy. We conclude that there is no justifiable reason to use a combination of Br and LD in early parkinsonian patients.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Floride</li>
<li>État de New York</li>
</region>
</list>
<tree><country name="États-Unis"><region name="État de New York"><name sortKey="Factor" sort="Factor" uniqKey="Factor" last="Factor">Factor</name>
</region>
<name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J." last="Weiner">William J. Weiner</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005D99 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005D99 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:3E9EB45C888D40961318899650513719A0D92969 |texte= Early combination therapy with bromocriptine and levodopa in parkinson's disease }}
This area was generated with Dilib version V0.6.23. |